S. Xiong

发表

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.

Huiling Yang, W. Delaney, C. Westland, 2004, Antiviral research.

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Michael D. Miller, C. Gibbs, E. Arnold, 2003, Journal of Virology.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

M. Wulfsohn, P. Marcellin, Z. Goodman, 2003, The New England journal of medicine.

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

M. Wulfsohn, E. Schiff, J. Villeneuve, 2003, Hepatology.

Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro

Michael D. Miller, C. Gibbs, Huiling Yang, 2004, Antimicrobial Agents and Chemotherapy.

Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV

Huiling Yang, W. Delaney, Michael I. Miller, 2005, Antiviral therapy.

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Michael D. Miller, Huiling Yang, W. Delaney, 2006, Antimicrobial Agents and Chemotherapy.

defovir Dipivoxil Alone or in Combination With Lamivudine in atients With Lamivudine-Resistant Chronic Hepatitis B

K. Kowdley, C. Trépo, P. Buggisch, 2003 .

Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection

B. Tennant, J. Gerin, P. Cote, 2008, Antimicrobial Agents and Chemotherapy.

Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection

W. Delaney, B. Tennant, J. Gerin, 2005, Antimicrobial Agents and Chemotherapy.

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

V. Calvez, T. Poynard, V. Thibault, 2006, Journal of hepatology.

Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B

P. Marcellin, J. Ma, Z. Goodman, 2005 .

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

C. Gibbs, J. Villeneuve, F. Zoulim, 2003, Journal of hepatology.

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

M. Wulfsohn, C. Gibbs, Huiling Yang, 2003, Hepatology.

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

C. Gibbs, P. Marcellin, R. Gish, 2003, Gastroenterology.

In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents

Huiling Yang, W. Delaney, Michael I. Miller, 2006, Antiviral therapy.

57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy

C. Gibbs, V. Thibault, S. Arterburn, 2004 .

Virus Activity of Tenofovir against Hepatitis B Intracellular Metabolism and In Vitro

Huiling Yang, W. Delaney, A. Ray, 2006 .

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

M. Wulfsohn, P. Marcellin, Z. Goodman, 2003, The New England journal of medicine.

Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

C. Gibbs, Huiling Yang, W. Delaney, 2002, Hepatology.

Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis

R. Ebrahimi, P. Buggisch, M. Peters, 2002 .

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Angeline Bartholomeusz, C. Gibbs, P. Angus, 2003, Gastroenterology.

Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients

E. Schiff, D. Samuel, N. Terrault, 2002 .

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

R. Rubin, K. Kowdley, R. Ebrahimi, 2004, Gastroenterology.

Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro

C. Gibbs, Huiling Yang, W. Delaney, 2002 .

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Graeme Currie, George Kitis, P. Marcellin, 2005, The New England journal of medicine.

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

C. Gibbs, P. Marcellin, R. Gish, 2003 .

Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, A. Neumann, 2003 .

Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients

M. Wulfsohn, C. Gibbs, W. Delaney, 2005, Journal of viral hepatitis.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

C. Gibbs, P. Marcellin, F. Zoulim, 2004, Gastroenterology.

46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES)

P. Marcellin, S. Lim, M. Rizzetto, 2004 .

Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy

Michael I. Miller, M. Wulfsohn, C. Gibbs, 2002 .

Lack of emerging resistance mutations in 467 HBeAg− and HBeAg+ patients with chronic hepatitis B receiving Adefovir Dipivoxil for 48 weeks

C. Gibbs, Huiling Yang, W. Delaney, 2002 .

Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection

M. Sherman, T. Wright, E. Heathcote, 2002 .

382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase

C. Gibbs, E. Arnold, K. Das, 2004 .

424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB)

P. Marcellin, Y. Liaw, M. Shiffman, 2004 .

Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy

M. Wulfsohn, C. Gibbs, Huiling Yang, 2003 .

Dynamics analyses provide insight into the influence of precore mutations on the mechanisms of viral CL

C. Gibbs, Huiling Yang, E. Heathcote, 2001 .

Original Articles: Viral HepatitisAdefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients☆

M. Wulfsohn, E. Schiff, J. Villeneuve, 2003 .

10 Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment

M. Wulfsohn, J. Villeneuve, F. Zoulim, 2003 .

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

C. Gibbs, P. Marcellin, F. Zoulim, 2004, Gastroenterology.